Description
Interspinous fixation (fusion) devices are being developed to aid in the stabilization of the spine. They are evaluated as alternatives to pedicle screw and rod constructs in combination with interbody fusion. Interspinous fixation devices (IFDs) are also being evaluated for stand-alone use in patients with spinal stenosis and/or spondylolisthesis.

For individuals who are undergoing spinal fusion who receive an IFD with interbody fusion, the evidence includes a systematic review of nonrandomized comparative studies and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity. There is a lack of evidence on the efficacy of IFDs in combination with interbody fusion. One risk is spinous process fracture, while a potential benefit is a reduction in adjacent segment degeneration. Randomized trials with longer follow-up are needed to evaluate the risks and benefits following use of IFDs compared with the established standard (pedicle screw-rod fixation). The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have spinal stenosis and/or spondylolisthesis who receive an IFD alone, the evidence includes a retrospective series. Relevant outcomes are symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity. There is a lack of evidence on the efficacy of IFDs as a stand-alone procedure. Randomized controlled trials are needed that evaluate health outcomes following use of IFDs when used alone for decompression. The evidence is insufficient to determine the effects of the technology on health outcomes.

Background
Contemporary models of interspinous fixation devices (IFDs) have evolved from spinous process wiring with bone blocks and early device designs (e.g., Wilson plate, Meurig-Williams system, Daab plate). The newer devices range from paired plates with teeth to U-shaped devices with wings that are attached to the spinous process. They are intended as an alternative to pedicle screw and rod constructs to aid in the stabilization of the spine with interbody fusion. IFDs are placed under direct visualization, while screw and rod systems may be placed under direct visualization or percutaneously. Use of an IFD in combination with a unilateral pedicle screw system has also been proposed. IFDs are not intended for stand-alone use.

For use in combination with fusion, it has been proposed that IFDs are less invasive and present fewer risks than pedicle or facet screws. While biomechanics studies have indicated that IFDs may be similar to pedicle screw-rod constructs in limiting the range of flexion and extension, they may be less effective than bilateral pedicle screw-rod fixation for limiting axial rotation and lateral bending.¹ There is a potential for a negative impact on the interbody cage and bone graft due to focal kyphosis resulting from the IFD. There is also a potential for spinous process fracture. 

Unlike IFDs, interspinous distraction devices (spacers) are used alone for decompression and are typically not fixed to the spinous process (see evidence review 7.01.107). In addition, interspinous distraction devices have been designed for dynamic stabilization, whereas IFDs are rigid. However, IFDs might also be used to distract the spinous processes and decrease lordosis. Thus, IFDs could be used off-label without interbody fusion as decompression (distraction) devices in patients with spinal stenosis. If IFDs are used alone as a spacer, there is a risk of spinous process fracture.

Regulatory Status
The following interspinous fixation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. This list may not be exhaustive.

• Aerial™ Interspinous Fixation (Globus Medical Inc.)

• Affix™ (NuVasive)

• Aileron™ (Life Spine)

• Aspen™ (Lanx, acquired by BioMet)

• Axle™ (X-Spine)

• BacFuse^® (Pioneer Surgical)

• BridgePoint™ (Alphatec Spine)

• coflex-IF^® (Paradigm Spine)

• Inspan™ (Spine Frontier)

• InterBRIDGE^® Interspinous Posterior Fixation System (LDR Spine)

• Minuteman™ (Spinal Simplicity)

• PrimaLOK™ (OsteoMed Spine)

• Octave™ (Life Spine)

• Spire™ (Medtronic)

• SP-Fix™ (Globus)

• SP-Link™ System (Medical Designs LLC)

• ZIP^® MIS Interspinous Fusion System (Aurora Spine).

FDA product code: PEK.

Interspinous fixation devices are intended for use as an adjunct to interbody fusion. For example, the indication for the coflex-IF^® implant is as:

"A posterior, nonpedicle supplemental fixation device intended for use with an interbody cage as an adjunct to fusion at a single level in the lumbar spine (L1 – S1). It is intended for attachment to the spinous processes for the purpose of achieving stabilization to promote fusion in patients with degenerative disc disease — defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies — with up to Grade 1 spondylolisthesis."

A number of interspinous plate systems have also been cleared for marketing by the FDA.

Use of an interspinous fixation device for a stand-alone procedure is considered off-label.   

Related Policies
701107 Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers)
701141 Lumbar Spinal Fusion

Policy
Interspinous fixation (fusion) devices are investigational and/or unproven and therefore considered NOT MEDICALLY NECESSARY for any indication, including but not limited to use:

• In combination with interbody fusion.

• Alone for decompression in patients with spinal stenosis.

Policy Guidelines
Clinical input has identified potential exceptions when the devices might be considered medically necessary, such as patients with small pedicles where pedicle screws could not be safely placed.

Coding
There are no specific CPT codes for insertion of these devices. The following code might be used:

+22840 Posterior non-segmental instrumentation (e.g., Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure).  

Benefit Application
BlueCard/National Account Issues
State or federal mandates (e.g., FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical uses of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trial are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Interspinous Fixation Device With Fusion
Clinical Context and Therapy Purpose
The purpose of interspinous fixation devices is to provide a treatment option that is an alternative to or an improvement on existing therapies for patients who are undergoing spinal fusion.

The question addressed in this evidence review is: Does the use of interspinous fixation improve the net health outcome in patients who are undergoing spinal fusion?

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients who are undergoing spinal fusion.

Interventions
The therapy being considered is interspinous fixation devices with interbody fusion.

Comparators
The following practice is currently being used for individuals who are undergoing spinal fusion: interspinous fixation devices with pedicle screw construct.

Outcomes
The general outcomes of interest include symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

• To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
• In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
• To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
• Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Systematic Reviews
A systematic review by Lopez et al. (2017) evaluated the literature on lumbar spinous process fixation and fusion devices.² Reviewers included both interspinous plates and fixation devices and excluded dynamic devices such as the X-Stop (see evidence review 701107). Fifteen articles met inclusion and exclusion criteria, including 4 comparative studies (level III evidence), 2 case series (level IV evidence), and 9 in vitro biomechanics studies (level V evidence). Two of the nonrandomized studies compared interspinous fixation devices with pedicle screws in patients undergoing interbody fusion and 2 included interspinous fixation devices alone or pedicle screws plus an interspinous fixation device in patients undergoing interbody fusion. Use of an interspinous fixation device decreased surgical time and blood loss compared with pedicle screws. No study showed that interspinous fixation devices reduced the hospital length of stay compared with pedicle screw implantation.

Randomized Controlled Trials
Subsequent to the systematic review by Lopez et al. (2017), 2 small RCTs (N = 149) have been published in individuals with single-level lumbar degenerative diseases undergoing spinal fusion who received an interspinous fixation device with interbody fusion as alternatives to pedicle screw and rod constructs (Table 1).^3,4 The first was a single-center study by Huang et al. (2017) that randomized 46 individuals to either an unknown type of interspinous fixation device or pedicle screws and followed them for 24 months.³ The second was a multicenter study by Panchal et al. (2018) that randomized 103 individuals to either the Aspen MIS Fusion System or pedicle screws and followed them for 12 months.⁴ Compared to the pedicle screw control groups (Table 2), similar or better fusion, disability, and quality of life outcomes were observed for the interspinous fixation device groups. Comparative complication rates were mixed across studies, but comparative treatment effects were not calculated. In the study by Panchal et al. (2018), revisions were numerically lower in the interspinous fixation device group, but comparative treatment effects were not calculated. Interpretation of these findings is limited by important weaknesses, however. In the RCT by Panchal et al. (2018), weaknesses included insufficient follow-up duration, lack of control for selection bias, and data incompleteness (Tables 3 and 4). In the RCT by Huang et al. (2017), weaknesses include unclear blinding of outcome assessors and potential use of a device that is not commercially available in the United States. Larger, longer-term, and more rigorous multicenter RCTs are needed to confirm these findings.

Table 1. Summary of Key RCT Characteristics

Study; Trial	Countries	Sites	Dates	Participants	Interventions
					Active	Comparator
Huang et al. (2017)3	China	1	2013 – 2014	Single-level lumbar degenerative diseases, including lumbar disc herniation, lumbar spinal stenosis, or lumbar degenerative spondylolisthesis	PLIF+ISF, N = 23	PLIF+pedicle screws, N = 23
Panchal et al. (2018)4	United States	9	NR	Single-level lumbar degenerative disc disease and/or spondylolisthesis (grade ≤ 2)	ALIF or LLIF +ISPF, N = 66	ALIF or LLIF + pedicle screws, N = 37

ALIF: anterior lateral lumbar interbody fusion; ISF: interspinous fastener (Wego, Weihai, China); ISPF: interspinous process fixation; LLIF: lateral lumbar interbody fusion; NR: not reported; PLIF: posterior lumbar interbody fusion; RCT: randomized controlled trial;
¹ Aspen MIS Fusion System, Zimmer Biomet Spine.

Table 2. Summary of Key RCT Results

Study	Fusion	Disability	Quality of life	Revisions	Overall Complications
Huang et al. (2017)3	43	43	N/A	N/A	43
Outcome definition	24-mo: radiograph/CT-scan	% of patients achieved MCID on ODI1	N/A	N/A
PLIF+ISP	17 (77%)/15 (68%)	33 (77%) overall2	NR	NR	2 (9%)
PLIF+pedicle scres	17 (81%)/16 (76%)		NR	NR	1 (5%)
p-value	1.000/0.736	NR	N/A	N/A	NR
Panchal et al. (2018)4	88	88	88	88	88
Outcome definition	12-mo radiographic fusion based on BSF-3/BSF-2/BSF-1 (95% CI)	ODI mean improvements ± SD at 12 mo	SF-36 physical component mean improvement ± SD at 12 mo	Required secondary surgical intervention	Rated as device-related/NOT device-related
ALIF or LLIF +ISPF	45.5% (32.7% – 59.6%)/45.5% (32.7% – 59.6%) /9.1% (0.0% – 23.2%)	25.97 ± 4.23	10.87 ± 2.79	1 (1.5%)	5 (7.5%)/14 (21.2%)
ALIF or LLIF + pedicle screws	50% (33.3% – 67.8%)/50% (3.3% – 67.8%)/0% (0.0% – 17.8%)	22.38 ± 5.84	9.10 ± 3.89	4 (10.8%)	6 (16.2%)/7 (18.9%)
p-value	0.33	< 0.01	≥ 0.22	NR	NR

ALIF: anterior lateral lumbar interbody fusion; BSF criteria: Brantigan, Stelfee, Fraser criteria: BSF-1, radiographic pseudoarthrosis with loss of intervertebral height with lucency around the implant; BSF-2, radiographic locked pseudoarthrosis with lucency within the cage but solid bone growth into the cage from each vertebral endplate;
and BSF-3, radiographic fusion with bony bridges in at least half of the fusion area; CI: confidence interval; ISF: interspinous fastener (Wego, Weihai, China); ISPF: interspinous process fixation; LLIF: lateral lumbar interbody fusion; MCID: minimally important clinical difference; N/A: not available; NR: not reported; ODI: Oswetry Disability Index; PLIF: posterior lumbar interbody fusion; RCT: randomized controlled trial; SD: standard deviation; SF-36: 36-Item Short Form Health Survey.
¹ MCID was prespecified as an 8-point difference.
² Did not stratify by group.

Table 3. Study Relevance Limitations

Study	Populationa	Interventionb	Comparatorc	Outcomesd	Follow-Upe
Huang et al. (2017)3		2. Version used unclear
Panchal et al. (2018)4					1. Not sufficient duration for benefit; 2. Not sufficient duration for harms

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.
^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4.Not the intervention of interest.
^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.
^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.
^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 4. Study Design and Conduct Limitations

Study	Allocationa	Blindingb	Selective Reportingc	Data Completenessd	Powere	Statisticalf
Huang et al. (2017)3	3. Allocation concealment unclear; “using closed envelopes”	3. Blinding unclear	1. Not registered
Panchal et al. (2018)4	4. Inadequate control for selection bias: More males (53% vs. 30%), on sick leave (23% vs. 5%) and with degenerative disk disease (55% vs. 43%)			1. High loss to follow-up or missing data (excluded 13% vs. 21% from 12-mo analysis); 6. Not intent to treat analysis (per protocol for noninferiority trials)

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.
^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.
^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician. 3. Blinding unclear
^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated

Section Summary: Interspinous Fixation Device With Fusion
The evidence for use of an interspinous fixation device with interbody fusion for those undergoing spinal fusion consists of a systematic review of nonrandomized comparative studies and case series and two small RCTs. The randomized trials found comparable benefits for interspinous fixation devices with interbody fusion for those undergoing spinal fusion compared with interbody fusion with pedicle screws, but the comparative safety was less clear. One risk is spinous process fracture, while a potential benefit is a reduction in adjacent segment degeneration. Additionally, the RCTs had important methodological and relevancy weaknesses that limited their interpretation. Randomized trials with longer follow-up are needed to evaluate the risks and benefits following use of interspinous fixation devices compared with the established standard (pedicle screw with rod fixation).

Interspinous Fixation Device as a Stand-Alone
Clinical Context and Therapy Purpose
The purpose of interspinous fixation devices is to provide a treatment option that is an alternative to or an improvement on existing therapies for patients with spinal stenosis and/or spondylolisthesis

The question addressed in this evidence review is: Does the use of interspinous fixation alone improve the net health outcome in patients who have spinal stenosis and/or spondylolisthesis?

The following PICO was used to select literature to inform this review.

Population
The relevant population of interest is patients who have spinal stenosis and/or spondylolisthesis.

Intervention
The therapy being considered is an interspinous fixation device alone.

Comparator
The following practice is currently being used to treat spinal stenosis and/or spondylolisthesis: decompression.

Outcomes
The general outcomes of interest include symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

• To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
• In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
• To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
• Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Case Series
Sclafani et al. (2014) reported on an industry-sponsored, retrospective series of the polyaxial PrimaLOK interspinous fusion device.⁵ Thirty-four patients were implanted with interspinous fixation devices alone, 16 patients received the PrimaLOK plus an interbody cage, and 3 patients received the PrimaLOK plus pedicle screw instrumentation and an interbody cage. Evaluation at 6 weeks found no cases of fracture or device migration, although there were 4 cases of hardware removal and 2 cases of reoperation for adjacent-level disease during follow-up. At a mean 22 months after the index surgery, the average pain score had improved from 7.2 to 4.5 on a 10-point scale (method of collection, e.g., visual analog scale, were not specified). There was a statistically significant improvement in pain score for patients with degenerative disc disease with lumbar stenosis (2.8; n = 25; p < 0.001) and spondylolisthesis (4.6; n = 6; p = 0.01), but not for patients with lumbar disc herniation (2.2; n = 10; p > 0.05).

Section Summary: Interspinous Fixation Device as a Stand-Alone
There is a lack of evidence (only a retrospective series) on the efficacy of interspinous fixation devices as a stand-alone procedure for those who have spinal stenosis and/or spondylolisthesis. RCTs are needed that evaluate health outcomes following use of interspinous fixation devices as a stand-alone for decompression.

Summary of Evidence
For individuals who are undergoing spinal fusion who receive an interspinous fixation device with interbody fusion, the evidence includes a systematic review of nonrandomized comparative studies and case series and 2 small RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity. The randomized trials found comparable benefits for interspinous fixation devices with interbody fusion for those undergoing spinal fusion compared with interbody fusion with pedicle screws, but the comparative safety was less clear. One risk is spinous process fracture, while a potential benefit is a reduction in adjacent segment degeneration. Additionally, the RCTs had important methodological and relevancy weaknesses that limited their interpretation. Randomized trials with longer follow-up are needed to evaluate the risks and benefits following use of interspinous fixation devices compared with the established standard (pedicle screw with rod fixation). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have spinal stenosis and/or spondylolisthesis who receive an interspinous fixation device alone, the evidence includes a retrospective series. Relevant outcomes are symptoms, functional outcomes, quality of life, resource utilization, and treatment-related morbidity. There is a lack of evidence on the efficacy of interspinous fixation devices as a stand-alone procedure. Randomized controlled trials are needed that evaluate health outcomes following use of interspinous fixation devices as a stand-alone for decompression. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from three physician specialty societies (two reviewers) and two academic medical centers while this policy was under review in 2012. Input was mixed. Some indications where the devices might be medically necessary were noted, such as patients with small pedicles where pedicle screws could not be safely placed.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

North American Spine Society
In 2019, the North American Spine Society issued a coverage position on the use of interspinous devices with lumbar fusion.⁶ The North American Spine Society noted that although there is still limited evidence, interspinous fixation with fusion for stabilization may be considered when utilized in the context of lumbar fusion procedures for patients with diagnoses including stenosis, disc herniations, or synovial facet cysts in the lumbar spine, as an adjunct to cyst excision which involves removal of greater than 50 percent of the facet joint and when utilized in conjunction with a robust open laminar and/or facet decortication and fusion, and/or a robust autograft inter- and extra-spinous process decortication and fusion, and/or an interbody fusion of the same motion segment. The North American Spine Society also noted that "No literature supports the use of interspinous fixation without performing an open decortication and fusion of the posterior bony elements or interbody fusion."

U.S. Preventive Services Task Force Recommendations
Not applicable

Ongoing and Unpublished Clinical Trials
Some currently unpublished and ongoing trials that might influence this evidence review are listed in Table 5.

Table 5. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing
NCT01455805a	Efficacy and Quality of Life Following Treatment of Lumbar Spinal Stenosis, Spondylolisthesis or Degenerative Disc Disease With the Minuteman Interspinous Interlaminar Fusion Implant Versus Surgical Decompression	50	March 2024
Unpublished
NCT01560273a	A Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis	25	Sep 2015 (terminated)
NCT01549366a	System Versus Pedicle Screw Fixation, in Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)	64	Jan 2016 (completed)

NCT: national clinical trial.
^a Denotes industry-sponsored or cosponsored trial.

References 

1. Wu JC, Mummaneni PV. Using lumbar interspinous anchor with transforaminal lumbar interbody fixation. World Neurosurg. May 2010; 73(5): 471-2. PMID 20920928
2. Lopez AJ, Scheer JK, Dahdaleh NS, et al. Lumbar Spinous Process Fixation and Fusion: A Systematic Review and Critical Analysis of an Emerging Spinal Technology. Clin Spine Surg. Nov 2017; 30(9): E1279-E1288. PMID 27438402
3. Huang WM, Yu XM, Xu XD, et al. Posterior Lumbar Interbody Fusion with Interspinous Fastener Provides Comparable Clinical Outcome and Fusion Rate to Pedicle Screws. Orthop Surg. May 2017; 9(2): 198-205. PMID 28544495
4. Panchal R, Denhaese R, Hill C, et al. Anterior and Lateral Lumbar Interbody Fusion With Supplemental Interspinous Process Fixation: Outcomes from a Multicenter, Prospective, Randomized, Controlled Study. Int J Spine Surg. Apr 2018; 12(2): 172-184. PMID 30276077
5. Sclafani JA, Liang K, Ohnmeiss DD, et al. Clinical outcomes of a polyaxial interspinous fusion system. Int J Spine Surg. 2014; 8. PMID 25694912
6. North American Spine Society (NASS). NASS coverage policy recommendations: Interspinous fixation with fusion. Revised December 2019. https://www.spine.org/Product-Details?productid=%7B7D67EEB8-4CC7-E411-9CA5-005056AF031E%7D. Accessed March 15, 2022.

Coding Section

Codes	Number	Description
CPT	22840	Posterior non-segmental instrumentation (e.g., Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure)
	22851 (deleted 1/1/2017)	Application of intervertebral biomechanical devices(s) — e.g., synthetic cages, methylmethacrylate, to vertebral defect or interspace.
	22853	Insertion of interbody biomechanical device(s) (e.g., Synthetic cage, mesh) with integral anterior instrumentation for device anchoring (e.g., screws, flanges), when performed, to intervertebral disc space in conjunction with interbody arthrodesis, each interspace (List separately in addition to code for primary procedure)
	22854	Insertion of intervertebral biomechanical device(s) (e.g., synthetic cage, mesh) with integral anterior instrumentation for device anchoring (e.g., Screws, flanges), when performed, to vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in conjunction with interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure)
	22859	Insertion of intervertebral biomechanical device(s) (e.g., synthetic cage, mesh, methylmethacrylate) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect (List separately in addition to code for primary procedure)
HCPCS	C1831 (effective 10/01/2021)	Personalized, anterior and lateral interbody cage (implantable)
ICD-10-CM (effective 10/01/15)		Investigational for all diagnoses
ICD-10-PCS (effective 10/01/15)		ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this procedure.
Type of Service
Place of Service

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2014 Forward     

06/06/2023	Annual review, no change to policy intent.
06/15/2022	Annual review, no change to policy intent. Updating rationale and references.
10/20/2021	Updating coding section adding code C1831 effective 10/01/2021. No other change.
06/01/2021	Annual review, no change to policy intent. Updating regulatory status, rationale and references.
06/16/2020	Annual review, no change to policy intent. Updating rationale and references.
06/04/2019	Annual review, no change to policy intent. Updating guidelines, rationale and references.
06/26/2018	Annual review, no change to policy intent. Updating rationale and references.
06/01/2017	Annual review, no change to policy intent. Updating background, description, rationale and references.
03/13/2017	Updated Coding section.
06/07/2016	Annual review, no change to policy intent. Updating background, description, regulatory status, rationale and references.
06/15/2015	Annual review, no change to policy intent. Updated regulatory status, rationale and references. Added coding.
06/04/2014	Annual review. Added policy guidelines. No change to policy intent.
06/04/2014	Computer Glich deleted policy. Created a duplicate of Orginal Policy.
06/05/2013	Initial Revision of Policy. Signatures by Mgmt was obtained during the time period of 06/06/13 through 06/10/2013. Policy went live on 06/13/2013.